Results 31 to 40 of about 14,652 (127)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting

Frontiers in Pharmacology, 2021
Background: To compare the effects of empagliflozin and linagliptin use on kidney outcomes of type 2 diabetes mellitus (T2DM) patients in a real-world setting.Methods: The study involved a propensity score-matched cohort comprising new users of ...
Yueh-Ting Lee, Chien-Ning Hsu, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li, Lung-Chih Li   +7 more
doaj   +1 more source

Empagliflozin: a new strategy for nephroprotection in diabetes

Сахарный диабет, 2017
Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes ...
Anton Ivanovich Korbut, Vadim Valer'evich Klimontov   +1 more
doaj   +1 more source

Empagliflozin Suppresses the Differentiation/Maturation of Human Epicardial Preadipocytes and Improves Paracrine Secretome Profile

JACC: Basic to Translational Science, 2023
Summary: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce epicardial adipose tissue (EAT) in humans, enhancing cardioprotective effects on heart failure and atrial fibrillation.
Masayuki Takano, MD, Hidekazu Kondo, MD, PhD, Taisuke Harada, MD, Masaki Takahashi, MD, Yumi Ishii, MD, PhD, Hirochika Yamasaki, MD, Tong Shan, MD, PhD, Kumiko Akiyoshi, MD, PhD, Takashi Shuto, MD, PhD, Yasushi Teshima, MD, PhD, Tomoyuki Wada, MD, PhD, Kunio Yufu, MD, PhD, Hidenori Sako, MD, PhD, Hirofumi Anai, MD, PhD, Shinji Miyamoto, MD, PhD, Naohiko Takahashi, MD, PhD   +15 more
doaj   +1 more source

Options for empagliflozin in combination therapy in type 2 diabetes mellitus

International Journal of General Medicine, 2016
Kenneth S Hershon1,2 1North Shore Diabetes and Endocrine Associates, New Hyde Park, 2Department of Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA Objective: To update clinicians with an overview of empagliflozin for the treatment of ...
Hershon KS
doaj  

Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background We determined if the sodium glucose co‐transporter 2 inhibitor empagliflozin attenuates pressure overload‐induced heart failure in non‐diabetic mellitus mice by direct cardiac effects and the mechanisms involved. Methods and Results Male C57BL/
Xuan Li, Qingguo Lu, Yunguang Qiu, Jussara M. do Carmo, Zhen Wang, Alexandre A. da Silva, Alan Mouton, Ana C. M. Omoto, Michael E. Hall, Ji Li, John E. Hall   +10 more
doaj   +1 more source

Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China

Frontiers in Cardiovascular Medicine, 2022
BackgroundThe Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) is the first randomized controlled trial to provide promising evidence on the efficacy of adding empagliflozin to the ...
Yaohui Jiang, Jun Xie
doaj   +1 more source

Empagliflozin [PDF]

Reactions Weekly, 2020
  +7 more sources

Attenuated Effects of Topical Empagliflozin on Imiquimod-induced Model of Psoriasis in Mice

Journal of Tropical Life Science
Empagliflozin is a sodium-glucose cotransporter inhibitor (SGLT2) that drops blood glucose levels by inhibiting glucose reabsorption and encouraging glucose excretion.
Alaa H. Abbas, Zahraa H Abbas, Hayder Ridha Salman, Hayder E Jabar, Abdulkareem H. Abd   +4 more
doaj   +1 more source

Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Cardiac arrest (CA) causes severe neurologic deficits and cognitive impairments. Empagliflozin is a newly developed antidiabetic drug and has been shown to reduce ischemia–reperfusion injury.
Peng Wang, Lian Liang, Yunke Tan, Qiulin Ge, Zitong Huang, Tao Yu   +5 more
doaj   +1 more source

Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin

JACC: Basic to Translational Science, 2019
Summary: The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular Outcome Trial of Empagliflozin) on heart failure (HF) outcome in patients with type 2 diabetes mellitus suggest a direct effect of empagliflozin ...
Rio P. Juni, PhD, Diederik W.D. Kuster, PhD, Max Goebel, MSc, Michiel Helmes, PhD, René J.P. Musters, PhD, Jolanda van der Velden, PhD, Pieter Koolwijk, PhD, Walter J. Paulus, MD, PhD, Victor W.M. van Hinsbergh, PhD   +8 more
doaj   +1 more source